ATLASNovo Nordisk A/S (NVO) Q3 2026 earnings results
Novo Nordisk A/S (NVO) reported EPS of $5.79 against an analyst estimate of $0.81: a beat of $4.98 (614.8%). The quarter ended Sep 30, 2026; the company reported on Wednesday, November 4, 2026, before the open.
Status: Confirmed · 14:37 ET, Nov 4 · Source: EODHD (calendar and fundamentals, cross-checked)
Get an email before and after Novo Nordisk A/S reports, free with your ATLAS account
Earnings alerts are a free benefit of your ATLAS account. The company goes to your watchlist and we email you when it reports. Google signup is one click.
Create free accountNVO Q3 2026 results at a glance
| EPS reported | $5.79 |
|---|---|
| EPS estimate | $0.81 |
| Surprise | Beat · +$4.98 (+614.8%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Nov 4, 2026, before the open |
| Status | Confirmed · 14:37 ET, Nov 4 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is Novo Nordisk A/S’s Q3 2026, a calendar-year company.
Novo Nordisk A/S EPS surprise history: last 5 quarters
Novo Nordisk A/S beat the EPS estimate in 4 of its last 5 reports, with an average surprise of +161.8%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Nov 4, 2026 | $0.81 | $5.79 | +614.8% | Beat | – |
| Aug 4, 2026 | $4.98 | $6.18 | +24.1% | Beat | -5.4% |
| May 6, 2026 | $6.96 | $6.63 | -4.7% | Miss | +2.1% |
| Feb 25, 2026 | $0.16 | $0.43 | +168.8% | Beat | -2.5% |
| Nov 5, 2025 | $4.24 | $4.50 | +6.1% | Beat | -3.6% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
NVO stock reaction to the report
The price reaction will be added after the Nov 4, 2026 close.
This section appears once a post-report closing price exists and updates with every new close.
Next NVO earnings report
Novo Nordisk A/S has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the NVO earnings calendar.
ATLAS fair value and signal for NVO
| Last price | $42.75 (+6.4%) |
|---|---|
| ATLAS fair value | $32.69 (range $24.29–$46.13) · price is 31% above it |
| Chance of a higher close in 1 month | 51% (normal range $40.65–$45.14) |
These are model outputs from the same valuation and calibrated model as the Novo Nordisk A/S stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Novo Nordisk A/S Q3 2026 earnings: frequently asked questions
Did Novo Nordisk A/S beat earnings estimates for Q3 2026?
Novo Nordisk A/S reported EPS of $5.79 against an analyst estimate of $0.81: a beat of $4.98 (614.8%).
When did Novo Nordisk A/S report Q3 2026 results?
Novo Nordisk A/S reported on Wednesday, November 4, 2026, before the open, for the quarter ended Wednesday, September 30, 2026.
How often does NVO beat EPS estimates?
In its last 5 reports with a recorded result, Novo Nordisk A/S beat the EPS estimate 4 times; the average surprise was +161.8%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer